Odevixibat by Ipsen for Biliary Atresia: Likelihood of Approval

Odevixibat is under clinical development by Ipsen and currently in Phase III for Biliary Atresia.

Intuitive CEO drills down on da Vinci 5 rollout, force feedback debate

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Intuitive Surgical’s da Vinci 5 robot launch,

January 16, 2025

Squaric acid dibutyl ester by Squarex Pharmaceutical for Herpes Labialis (Oral Herpes): Likelihood of Approval

Squaric acid dibutyl ester is under clinical development by Squarex Pharmaceutical and currently in Phase I for Herpes Labialis (Oral Herpes).

February 22, 2024

Better Data for Better Health Among Medicaid Recipients

Adam Rarick-Varner, Sr. Director of Healthcare Strategy, LexisNexis Risk Solutions During the peak of the Covid-19 pandemic, over 10 million Americans enrolled in Medicaid –

November 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.